The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on primitive hematopoietic stem cell (PHSC) function and numbers, after chemotherapy

被引:17
作者
Gardner, RV [1 ]
Begue, R [1 ]
McKinnon, E [1 ]
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70112 USA
关键词
D O I
10.1016/S0301-472X(01)00685-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Primitive hematopoietic stem cell function was assessed after cyclophosphamide with granulocyte-macrophage colony-stimulating factor (GM-CSF), with or without preadministration of interleukin-1, using competitive repopulation. Methods. C57B6/J mice injected with one or four biweekly intravenous injections of cyclophosphamide, 200 mg/kg, received granulocyte-macrophage colony-stimulating factor, 1 mug, subcutaneously for 5 days, beginning 24 hours after cyclophosphamide. Alternatively, mice were injected with interleukin-1, 1 mug, 20 hours before administration of drug or drug and cytokine. Marrow obtained from mice sacrificed 4 weeks after the last dose of drug or drug and cytokine was used in competitive repopulation. Results. Significant reductions in marrow repopulating ability occurred after a single dose of cyclophosphamide or multiple injections. Repopulating units (RU) were calculated, and both binomial and Poisson models for estimation of primitive hematopoietic stem cell PHSC numbers were used. RU were significantly diminished for all treatment groups when compared to controls. PHSC numbers were not significantly affected by either regimen of cyclophosphamide given alone. Addition of GM-CSF to cyclophosphamide, whether the latter was given in single or multiple doses, led to further, although insignificant, declines in repopulating ability, as well as PHSC and RU numbers. Interleukin-1 usage exacerbated the observed repopulating defect. There was evidence of replicative failure in individual cells, indicating a qualitative defect also. Summary. Additive stem cell depletion and qualitative replicative defect occur after chemotherapy-cytokine usage. However, the replicative defect of PHSC seen after addition of GMCSF is not significantly worse than that seen with cytotoxic drug use alone. (C) 2001 International Society for Experimental Hematology. Published by Elsevier Science Inc.
引用
收藏
页码:1053 / 1059
页数:7
相关论文
共 48 条
  • [1] EFFECT OF RECOMBINANT HUMAN GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR ON CHEMOTHERAPY-INDUCED MYELOSUPPRESSION
    ANTMAN, KS
    GRIFFIN, JD
    ELIAS, A
    SOCINSKI, MA
    RYAN, L
    CANNISTRA, SA
    OETTE, D
    WHITLEY, M
    FREI, E
    SCHNIPPER, LE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (10) : 593 - 598
  • [2] BAIOCCHI G, 1993, CANCER RES, V53, P1297
  • [3] BONNET D, 1993, BLOOD, V82, P3307
  • [4] CASTELLI MP, 1988, J IMMUNOL, V140, P3830
  • [5] Development and aging of primitive hematopoietic stem cells in BALB cBy mice
    Chen, JC
    Astle, CM
    Harrison, DE
    [J]. EXPERIMENTAL HEMATOLOGY, 1999, 27 (05) : 928 - 935
  • [6] Clarke V, 1999, MED PEDIATR ONCOL, V32, P331, DOI 10.1002/(SICI)1096-911X(199905)32:5<331::AID-MPO4>3.0.CO
  • [7] 2-M
  • [8] DAINIAK N, 1992, EXP HEMATOL, V20, P1154
  • [9] DALMAU SR, 1993, BONE MARROW TRANSPL, V12, P551
  • [10] Prophylactic pretreatment of mice with hematopoietic growth factors induces expansion of primitive cell compartments and results in protection against 5-fluorouracil-induced toxicity
    deHaan, G
    Dontje, B
    Engel, C
    Loeffler, M
    Nijhof, W
    [J]. BLOOD, 1996, 87 (11) : 4581 - 4588